An analysis of the HAPO Follow-up Study is shedding light on associations between birth weight categories and risk of diabetes 10-14 years after delivery in mothers.
New research suggests a large-for-gestational age (LGA) birth was linked to a 21% increase in likelihood of having prediabetes or diabetes later in life.
Presented at the Society for Maternal-Fetal Medicine’s annual Pregnancy Meeting, results of the analysis of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-up Study indicate a diagnosis of prediabetes or diabetes 10-14 years after delivery occurred among nearly 25% of all women who had a LGA birth.1
“So often in clinical practice when we see big babies and the individual doesn’t have gestational diabetes, we do not talk about the health consequences for the mother later in life,” said lead investigator Kartik K. Venkatesh, MD, PhD, a maternal-fetal medicine subspecialist and assistant professor of obstetrics and gynecology and assistant professor of epidemiology at The Ohio State University Wexner Medical Center, in a statement.2 “But this research suggests there may also be health consequences for the pregnant person even without gestational diabetes when they have a larger than normal sized infant. That’s why it’s so important to follow large groups of people and their babies, regardless of whether they had gestational diabetes or not, over a long period of time.”
Although extensive research has been conducted examining potential associations between LGA births and gestational diabetes, Venkatesh and fellow investigators point out much less has been examined in the area of LGA birth and diabetes later in life. Citing this lack of research, investigators launched the current research endeavor with the intent of providing clinicians with a more comprehensive overview of associations between LGA and small-for-gestational age (SGA) births with development of prediabetes and diabetes later in life relative to those with appropriate for gestational age (AGA) births.1
With this in mind, investigators designed their study as an analysis of the HAPO Follow-up Study. An observational study led by investigators from the Northwestern University Feinberg School of Medicine3, the HAPO Follow-up study provided investigators with data related to 4025 women without gestational diabetes mellitus for inclusion in the current study. This cohort had a median age of 30.2 (interquartile range [IQR], 25.-7-33.8) years. Among the 4025 included in the current study, 13.2% had a LGA infant, 7.8% had a SGA infant, and 78.9% had an AGA infant.1
The primary exposures of interest for the study were birthweight category of mothers. Investigators used Poisson regression with adjustment for baseline maternal covariates to assess associations between exposures of interest and the development of prediabetes or diabetes by 10-14 years after delivery. Investigators noted covariates included age, parity, body mass index, height, family history of diabetes, mean arterial pressure, smoking status, and alcohol use.1
During the follow-up period, 20.0% were diagnosed with prediabetes or diabetes by 10-14 years after delivery. Initial analysis indicated frequency of prediabetes or diabetes was highest among those who had a LGA birth (24.8%) compared to those with an AGA birth (19.7%), but the lowest frequency was observed among those with a SGA birth (P <.01). In adjusted analyses, results indicated those who had a LGA birth had a greater risk of developing prediabetes or diabetes compared to those with an AGA birth (adjusted risk ratio [aRR], 1.21 [95% CI, 1.02-1.44]). In the same model, those who had a SGA birth had a lower risk of developing prediabetes or diabetes compared to those with an AGA birth (aRR, 0.81 [95% CI, 0.62-1.07]).1
“The real implication of this research is that we need to stop thinking of pregnancy care as episodic care by making these connections between pregnancy and long-term health outcomes in mothers and children in order to see the bigger picture,” Venkatesh added.2
This article was originally published by our sister publication HCP Live.
References
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Early pregnancy cannabis use high in states with recreational legalization
November 11th 2024A population-based time-series analysis California before, during and after legalization show a rising trend in women using cannabis while pregnancy especially when the state has legalized the drug.
Read More
Maternal hidradenitis suppurativa linked to higher pregnancy risks
November 6th 2024A study of over 1 million births in Quebec reveals that pregnant women with hidradenitis suppurativa face increased risks of pregnancy complications and long-term health issues for both themselves and their offspring.
Read More